GlassScriptPhysician profile
Heather Rogers
NPI 1528637204
$3,475.49
in general payments reported to CMS, 2019-2025
19 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $354 · 2024: $1,475 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $753.28 | 2023-2025 | Caplyta |
| Abbvie INC. | $751.71 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $666.99 | 2023-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $393.03 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $196.95 | 2023-2024 | Austedo Xr, Uzedy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.25 | 2022 | |
| Supernus Pharmaceuticals, INC. | $88.33 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $69.81 | 2024-2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $68.55 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $57.02 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $53.47 | 2024 | Trintellix |
| Almatica Pharma LLC | $50.27 | 2024 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $45.32 | 2025 | Cobenfy |
| Alkermes, INC. | $38.88 | 2023-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $37.39 | 2024-2025 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.14 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $32.51 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.34 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $16.25 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.